The company ended the quarter with $192 million in cash and equivalents, enough to fund operations past 2027. 2seventy Bio ...

FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW YORK, Nov. 13, ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Vivek Ramaswamy has withdrawn from the Ohio Senate race to support Trump’s initiative with Elon Musk on government efficiency ...

MEMS, wearable/implantable electronics and bio-tissue therapeutics, the pursuit of piezoelectric biomaterials has become a ...

Ariel Investments, an investment management company, released its “Ariel Focus Fund” third-quarter 2024 investor letter. A ...

bluebird bio BLUE is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement. Analysts estimate that bluebird bio will ...

"We are excited to have completed administering first doses to all patients enrolled in our phase 2 Alzheimer's trial,” ...

Binance Labs has invested in BIO Protocol, a pioneering protocol transforming the way early-stage scientific research is ...

Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside ...

World Bio Summit South Korean Health Minister Cho Kyoo-hong and other participants pose during the World Bio Summit 2024 at a ...